Nkarta, Inc. (NKTX:NASDAQ) closed at $2.08 on October 14, 2026, down 0.95% on the day. The stock trades 44.1% below its 52-week high of $3.72 and 22.4% above its 52-week low of $1.70. Over the past year, it lost 12.1%. Nkarta, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -6.67% | -28.08% | -19.23% | -39.48% | -12.13% |
In 252 trading sessions since October 13, 2025, NKTX closed higher on 120 days (48%). Its best day was April 17, 2026 (+23.93%) and its worst was July 9, 2026 (-12.53%). The stock moved 10% or more in a single session 7 times.
Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment.
Find more stocks like NKTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.